A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme.

Oncotarget · 2015 · PMC4745707 · PMID 26338962

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Staining of ICAM1 in tumors from these patients showed a trend towards higher expression of ICAM1 in patients who did benefit from ipilimumab, however these results were not statistically significant, probably due to the small sample size.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.